VIRIOS THERAPEUTICS INC (VIRI)       0.3566  +0.02 (+6.42%)

0.3566  +0.02 (+6.42%)

US92829J1043 - Common Stock - After market: 0.3567 +0 (+0.03%)


Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VIRI. VIRI was compared to 641 industry peers in the Biotechnology industry. VIRI has a bad profitability rating. Also its financial health evaluation is rather negative. VIRI has a expensive valuation and it also scores bad on growth

Note: VIRI has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

VIRI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of VIRI.

VS Industry

Valuation

Valuation Rating

2

When comparing the current price to the book value of VIRI, it is valued rather cheaply. It is trading at 0.71 times its book value.
When comparing the price book ratio of VIRI to the average industry price book ratio of 1.91, VIRI is valued rather cheaply.

The Price/Earnings Ratio is negative for VIRI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIRI. No positive earnings are expected for the next year.
VS Industry

Price/Book (0.71) VS Industry: 78% outperformed.

440.81
0.07

Growth

Growth Rating

3

VIRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.59%, which is quite impressive.

Based on estimates for the next 5 years, VIRI will show a small growth in Earnings Per Share. The EPS will grow by 9.52% on average per year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 33.59% 42.44% 28.21% 19.69% 9.52%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

3

A Current Ratio of 6.65 indicates that VIRI has no problem at all paying its short term obligations.
VIRI has a Quick Ratio of 6.65. This indicates that VIRI is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio is in line with the industry averages, which is at 6.18.
The Quick Ratio is in line with the industry averages, which is at 6.05.

The Debt to Equity ratio of VIRI is in line with the industry averages.
Based on the Altman-Z score of -8.08, we must say that VIRI is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.14, VIRI is in worse financial state than most of its industry peers. 81% of its industry peers have a better Altman-Z score.
The Piotroski-F score of VIRI is 3.00. This is a low score and indicates issues in the health and profitability of VIRI.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (6.65) VS Industry: 54% outperformed.

0.04
84.53

Current Ratio (6.65) VS Industry: 54% outperformed.

0.08
85.09

Altman-Z (-8.08) VS Industry: 19% outperformed.

-2,797.49
667.93

Dividend

Dividend Rating

0

VIRI does not give a dividend.

VIRIOS THERAPEUTICS INC0.3566

NASDAQ:VIRI (2/7/2023, 7:12:35 PM)+0.02 (+6.42%)

After market: 0.3567 +0 (+0.03%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) N/A N/A
Inst Owners 6.95% Inst Owner Change -1.25%
Ins Owners 4.07% Ins Owner Change -0.24%
Market Cap 6.54M Analysts 43.33
Price Target 2.04 (472.07%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 29.28%
Min EPS beat(2) 14.58% Max EPS beat(2) 43.98%
EPS beat(4) 4 Avg EPS beat(4) 23.04%
Min EPS beat(4) 12.04% Max EPS beat(4) 43.98%
Revenue beat(2) N/A Avg Revenue beat(2) N/A
Min Revenue beat(2) N/A Max Revenue beat(2) N/A
Revenue beat(4) N/A Avg Revenue beat(4) N/A
Min Revenue beat(4) N/A Max Revenue beat(4) N/A
PT rev (1m) 0% PT rev (3m) 0%
EPS NQ rev (1m) 0% EPS NQ rev (3m) 68.69%
EPS NY rev (1m) 0% EPS NY rev (3m) 37.89%
Revenue NQ rev (1m) N/A Revenue NQ rev (3m) N/A
Revenue NY rev (1m) N/A Revenue NY rev (3m) N/A

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM) -1.74 EY N/A
EPS(NY) -0.74 Fwd EY N/A
FCF(TTM) -0.76 FCFY N/A
OCF(TTM) -0.76 OCFY N/A
SpS N/A BVpS 0.5
TBVpS 0.5 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 3 Asset Turnover N/A

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Profit Quality N/A
Current Ratio 6.65
Quick Ratio 6.65
Altman-Z -8.08
F-Score 3 WACC N/A
ROIC/WACC N/A Cap/Depr(3y) N/A
Cap/Depr(5y) N/A Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 33.59% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 42.86%
EPS Next Y 42.44% EPS Next 2Y 28.21%
EPS Next 3Y 19.69% EPS Next 5Y 9.52%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
EBIT growth 1Y 19.37% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y -571.85% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -571.85%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA